Evaxion Biotech A/S Statistics
Share Statistics
Evaxion Biotech A/S has 1.4M
shares outstanding. The number of shares has increased by 0.02%
in one year.
| Shares Outstanding | 1.4M |
| Shares Change (YoY) | 0.02% |
| Shares Change (QoQ) | -0.48% |
| Owned by Institutions (%) | 15.81% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 60 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 18.56K, so 0.29% of the outstanding
shares have been sold short.
| Short Interest | 18.56K |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.39% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.43 and the forward
PE ratio is -1.
Evaxion Biotech A/S's PEG ratio is
0.01.
| PE Ratio | -0.43 |
| Forward PE | -1 |
| PS Ratio | 1.36 |
| Forward PS | 0 |
| PB Ratio | -2.75 |
| P/FCF Ratio | -0.35 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Evaxion Biotech A/S.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01,
with a Debt / Equity ratio of -6.11.
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Debt / Equity | -6.11 |
| Debt / EBITDA | -1.03 |
| Debt / FCF | -0.78 |
| Interest Coverage | -15.31 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $72,695.65 |
| Profits Per Employee | $-229,717.39 |
| Employee Count | 46 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -788K |
| Effective Tax Rate | 6.94% |
Stock Price Statistics
The stock price has increased by -90.31% in the
last 52 weeks. The beta is -0.23, so Evaxion Biotech A/S's
price volatility has been lower than the market average.
| Beta | -0.23 |
| 52-Week Price Change | -90.31% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 7.33 |
| Relative Strength Index (RSI) | 61.31 |
| Average Volume (20 Days) | 77,475 |
Income Statement
In the last 12 months, Evaxion Biotech A/S had revenue of 3.34M
and earned -10.57M
in profits. Earnings per share was -10.
| Revenue | 3.34M |
| Gross Profit | 3.34M |
| Operating Income | -14.73M |
| Net Income | -10.57M |
| EBITDA | -9.77M |
| EBIT | -10.39M |
| Earnings Per Share (EPS) | -10 |
Full Income StatementBalance Sheet
The company has 5.05M in cash and 10.1M in
debt, giving a net cash position of -5.05M.
| Cash & Cash Equivalents | 5.05M |
| Total Debt | 10.1M |
| Net Cash | -5.05M |
| Retained Earnings | -118.54M |
| Total Assets | 12.48M |
| Working Capital | 4.4M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.94M
and capital expenditures 0, giving a free cash flow of -12.94M.
| Operating Cash Flow | -12.94M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.94M |
| FCF Per Share | -0.6 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -440.55% and -316%.
| Gross Margin | 100% |
| Operating Margin | -440.55% |
| Pretax Margin | -339.56% |
| Profit Margin | -316% |
| EBITDA Margin | -292.14% |
| EBIT Margin | -440.55% |
| FCF Margin | -386.96% |
